ReviewJournal of the American Society of Nephrology : JASN2014
Challenges and advances in the treatment of AKI.
Review in Journal of the American Society of Nephrology : JASN, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02530359 (Pirfenidone Effect on the Recovery of Renal Function in Patients With Septic Acute Kidney Injury), which is not on this map. Cited by 54 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pirfenidone Effect on the Recovery of Renal Function in Patients With Septic Acute Kidney Injury
Who cites it
54 citing papers in PubMed.
- Urinary UDP-sugars provide actionable prediction of acute kidney injury in cardiac surgery patients.American journal of physiology. Heart and circulatory physiology · 2026Article
- Repositioning of Ertiprotafib via supramolecular assembly enables biomarker-guided therapy for acute kidney injury.Journal of nanobiotechnology · 2026Article
- Cpd-A1 alleviates acute kidney injury by inhibiting ferroptosis.Acta pharmacologica Sinica · 2024Article
- [Emergencies in nephrology].Innere Medizin (Heidelberg, Germany) · 2024Review
- WTAP-mediated N6-methyladenosine modification promotes the inflammation, mitochondrial damage and ferroptosis of kidney tubular epithelial cells in acute kidney injury by regulating LMNB1 expression and activating NF-κB and JAK2/STAT3 pathways.Journal of bioenergetics and biomembranes · 2024Article
- Serotonin regulation of mitochondria in kidney diseases.Pharmacological research · 2024Review
- ISG15 accelerates acute kidney injury and the subsequent AKI-to-CKD transition by promoting TGFβR1 ISGylation.Theranostics · 2024Article
- Integrated Analysis of Blood and Urine Biomarkers to Identify Acute Kidney Injury Subphenotypes and Associations With Long-term Outcomes.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2023Article
- HBSP improves kidney ischemia-reperfusion injury and promotes repair in properdin deficient miceFrontiers in immunology · 2023Article
- Article
- Article
- TLR2/caspase-5/Panx1 pathway mediates necrosis-induced NLRP3 inflammasome activation in macrophages during acute kidney injury.Cell death discovery · 2022Article
- Extracellular CIRP induces acute kidney injury via endothelial TREM-1.Frontiers in physiology · 2022Article
- Decoy Receptor 3 Suppresses T-Cell Priming and Promotes Apoptosis of Effector T-Cells in Acute Cell-Mediated Rejection: The Role of Reverse Signaling.Frontiers in immunology · 2022Article
- Indispensable role of mitochondria in maintaining the therapeutic potential of curcumin in acute kidney injury.Journal of cellular and molecular medicine · 2021Article
- Chronic Kidney Disease: Strategies to Retard Progression.International journal of molecular sciences · 2021Review
- Kidney Microcirculation as a Target for Innovative Therapies in AKI.Journal of clinical medicine · 2021Review
- Therapeutic Potential of Mesenchymal Stromal Cell-Derived Extracellular Vesicles in the Prevention of Organ Injuries Induced by Traumatic Hemorrhagic Shock.Frontiers in immunology · 2021Review
- High salt exacerbates acute kidney injury by disturbing the activation of CD5L/apoptosis inhibitor of macrophage (AIM) protein.PloS one · 2021Article
- New insights into the role of heme oxygenase-1 in acute kidney injury.Kidney research and clinical practice · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treating or preventing AKI requires treating or preventing a rise in serum creatinine as well as the immediate and remote clinical consequences associated with AKI. Because a substantial number of patients with AKI progress to ESRD, identifying patients likely to progress and halting progression are important goals for treating AKI. Many therapies for AKI are being developed, including RenalGuard Therapy, which aims to maintain high urine output; α-melanocyte-stimulating hormone, with anti-inflammatory and antiapoptotic activities; alkaline phosphatase, which detoxifies proinflammatory substances; novel, small interfering RNA, directed at p53 activation; THR-184, a peptide agonist of bone morphogenetic proteins; removal of catalytic iron, important in free-radical formation; and cell-based therapies, including mesenchymal stem cells in vivo and renal cell therapy in situ. In this review, we explore what treatment of AKI really means, discuss the emerging therapies, and examine the windows of opportunity for treating AKI. Finally, we provide suggestions for accelerating the pathways toward preventing and treating AKI, such as establishing an AKI network, implementing models of catalytic philanthropy, and directing a small percentage of the Medicare ESRD budget for developing therapies to prevent and treat AKI and halt progression of CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.